Current Report · Items 5.02, 9.01 · 8-K

Cingulate Inc.

CINGNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Oct 2, 2026Accepted Oct 2, 2026, 4:30 PM EDTCIK 1862150Accession 0001493152-26-045527

Company context

We are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer (“EBL”) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. We believe there remains a significant, unmet need within the current treatment paradigm for true once-daily ADHD stimulant medications with lasting duration and a superior side effect profile to better serve the needs of patients throughout their entire active-day.

Current securities

CINGNASDAQ · EQUITY · Current CINGWNASDAQ · WARRANT · Current

Recent company filings

Registered securities in this filing

CINGULATE INC. · 8-K · Filed 2026-10-02

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: CING
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: From2026-09-302026-09-30_custom_CommonStockParValue0.0001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, exercisable for common stock

Symbol: CINGW
Exchange: NASDAQ
Classification: WARRANT
Status: Current

Filing context

Context: From2026-09-302026-09-30_custom_WarrantsExercisableForCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226045527 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item Departure 5.02. of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”), entered into amendment No. 2 (the “Amendment”) to the Employment Agreement between Matthew N. Brams, Executive Vice President and Chief Medical Officer, and CTx, effective January 1, 2026. Pursuant to the Amendment, the Trial Period (as defined in the Amendment) for Mr. Brams’ full-time employment was extended from September 30, 2026 to December 31, 2026. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Get the free weekly BCS email.